Advancing Chronic Disease Management with Ultra Long-Acting Miniature Subdermal Implants of GLP-1
Time: 4:20 pm
day: Conference Day One
Details:
- Exploring the NanoPortal™ implant technology, emphasizing its design for consistent drug delivery
- Insights on NPM-115 and NPM-119 and the LIBERATE-1 study evaluating the efficacy of the six-month exenatide implants for obesity and type 2 diabetes
- Exploration of the potential impact of ultra-long-acting implants on chronic disease management and advancements in alternative drug delivery methods
